Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
National Heart, Lung, and Blood Institute (NHLBI) Blood and Marrow Transplant Clinical Trials Network National Cancer Institute (NCI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00849147 |
Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients.
This study will evaluate the effectiveness of a new type of bone marrow transplant—one that uses lower doses of chemotherapy and bone marrow donated from family members with only partially matched bone marrow—in people with leukemia or lymphoma.
Condition | Intervention | Phase |
---|---|---|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid, Acute Burkitt Lymphoma Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse |
Biological: Haploidentical Bone Marrow Transplantation |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603) |
Estimated Enrollment: | 50 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | August 2014 |
Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Participants will receive a human leucocyte antigen (HLA)-haploidentical bone marrow transplant using a non-myeloablative preparative regimen.
|
Biological: Haploidentical Bone Marrow Transplantation
The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor. The GVHD prophylaxis regimen will consist of the following:
|
Leukemia and lymphoma are types of blood cancers. Chemotherapy is a common treatment option for people with these types of cancers, but if the cancer does not respond well to chemotherapy, or if the cancer returns, a bone marrow transplant is another treatment option. In a bone marrow transplant procedure, healthy bone marrow is taken from a donor and transplanted into the patient. Bone marrow can be donated by a family member or an unrelated donor who has a similar type of bone marrow. Most bone marrow transplants are performed using a donor who is a perfect or close-to-perfect tissue match. However, for participants in this study, researchers have determined that a completely matched donor is unavailable within participants' families, and an unrelated donor match has not been found either. Participants do, however, have a family member who is a partial tissue match.
Typically, people who are undergoing a bone marrow transplant receive high doses of chemotherapy before the transplant to prepare their bodies to accept the donor bone marrow. In this study, participants will undergo a new type of bone marrow transplant called a nonmyeloablative transplant, which is a reduced intensity method of transplantation that does not require high doses of chemotherapy. The purpose of the study is to examine the safety and effectiveness of a nonmyeloablative bone marrow transplant that uses partially matched bone marrow donated by a family member as a treatment option for people with leukemia or lymphoma.
This study will enroll people with leukemia or lymphoma who have a family member with a partial tissue match.
Participants will be admitted to the hospital and will first receive a type of chemotherapy called fludarabine, which will be given intravenously for 5 days. In addition, another type of chemotherapy, cyclophosphamide, will be given intravenously on the first and second day. After 5 days, participants will receive a small dose of radiation. The next day, participants will undergo the bone marrow transplant. The third and fourth day after the transplant, participants will receive high doses of cyclophosphamide to help prevent two complications, graft rejection, which occurs when the body's immune system rejects the donor bone marrow, and graft-versus-host disease (GVHD), which is an attack by the donor cells on the body's normal tissues. On the fifth day after the transplant, participants will receive two additional medications, tacrolimus and mycophenolate mofetil (MMF), to help prevent GVHD; some participants may receive cyclosporine instead of tacrolimus. Participants will receive MMF for about 5 weeks and tacrolimus for about 6 months. Also beginning on the fifth day after the transplant, participants will receive daily injections of a growth factor called granulocyte-colony stimulating factor (G-CSF), which is a natural protein that increases the white blood cell count; G-CSF will be continued until a participant's white blood cell count is normal again.
Participants will remain in the hospital for approximately 2 to 3 months, but possibly longer if there are complications. While participants are in the hospital, blood samples will be collected regularly to evaluate the response and possible side effects to treatment, including GVHD. If necessary, participants will receive platelet and red blood cell transfusions. Follow-up study visits will occur 6 months and 1 year after the transplant. At Months 1, 2, 6, and 12 after the transplant, blood or bone marrow samples will be obtained. Study researchers will keep track of participants' medical condition through phone calls or mailings to participants and their doctors once a year for the rest of the participants' lives.
Ages Eligible for Study: | 1 Year to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Fulfillment of this criterion shall be considered sufficient evidence that the donor and recipient share one HLA haplotype, and typing of additional family members is not required.
Patients with adequate physical function as measured by the following:
Exclusion Criteria:
Contact: Sandi Sykes | 301-251-1161 ext 177 | bmtctn@emmes.com |
Study Director: | Mary Horowitz, MD, MS | Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin |
Responsible Party: | National Heart, Lung, and Blood Institute ( Nancy DiFronzo, PhD, Project Officer ) |
Study ID Numbers: | 605, U01 HL069294 |
Study First Received: | February 20, 2009 |
Last Updated: | July 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00849147 History of Changes |
Health Authority: | United States: Federal Government |
Acute Lymphoblastic Leukemia/Lymphoma Acute Myelogenous Leukemia Mantel-Cell Lymphoma |
Hematopoietic Transplant Haplo-Identical Transplant Non-Myeloablative Transplant |
Leukemia, Lymphoid Benzocaine Lymphoma, Follicular Tacrolimus Cyclophosphamide Leukemia, Myeloid, Acute Follicular Lymphoma Lymphoma, B-Cell Leukemia Acute Myelocytic Leukemia Acute Myeloid Leukemia, Adult Mycophenolate mofetil Epstein-Barr Virus Infections Lymphoma Acute Lymphoblastic Leukemia |
Lymphoma, Large B-Cell, Diffuse Precursor Cell Lymphoblastic Leukemia-Lymphoma Immunoproliferative Disorders Fludarabine monophosphate Leukemia, Myeloid Herpesviridae Infections Virus Diseases Lymphatic Diseases Burkitt's Lymphoma Precursor B-Cell Lymphoblastic Leukemia-Lymphoma B-cell Lymphomas Burkitt Lymphoma DNA Virus Infections Fludarabine Lymphoma, Non-Hodgkin |
Leukemia, Lymphoid Lymphoma, Large B-Cell, Diffuse Immunoproliferative Disorders Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma Immune System Diseases Tumor Virus Infections Lymphoma, Follicular Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms, Experimental Herpesviridae Infections |
Virus Diseases Lymphoma, B-Cell Lymphatic Diseases Leukemia Neoplasms Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Burkitt Lymphoma DNA Virus Infections Epstein-Barr Virus Infections Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |